Human Epstein-Barr virus early antigen diffuse (EBV-EA-D) IgG ELISA Kit (DEIA329)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Serum, plasma
Intended Use
The ELISA test kit provides semiquantitative or quantitative in vitro determination of human antibodies of the immunoglobulin class IgG against Epstein-Barr virus early antigen diffuse (EBV-EA-D) in serum or plasma to support the diagnosis of infectious mononucleosis.
Contents of Kit
1. Microplate wells coated with antigens, 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use,12 x 8
2. Calibrator 1, 200 RU/ml (IgG, human), ready for use, dark red, 1 x 2.0 ml
3. Calibrator 2, 20 RU/ml (IgG, human), ready for use, red 1 x 2.0 ml
4. Calibrator 3, 2 RU/ml (IgG, human), ready for use, light red, 1 x 2.0 ml
5. Positive control, (IgG, human), ready for use, blue 1 x 2.0 ml
6. Negative control, (IgG, human), ready for use green 1 x 2.0 ml
7. Enzyme conjugate, peroxidase-labelled anti-human IgG (rabbit), ready for use, green, 1 x 12 ml
8. Sample buffer, ready for use, light blue, 1 x 100 ml
9. Wash buffer, 10x concentrate, colourless, 1 x 100 ml
10. Chromogen/substrate solution, TMB/H2O2, ready for use, colourless, 1 x 12 ml
11. Stop solution, 0.5 M sulphuric acid, ready for use, colourless, 1 x 12 ml
12. Test instruction --- 1 booklet
13. Quality control certificate --- 1 protocol
The test kit has to be stored at a temperature between +2°C and +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.
Performance Characteristics
As no international reference serum exists for antibodies against EBV-EA-D, the calibration is performed in relative units (RU). For every group of tests performed, the extinction readings of the calibrators and the relative units and/or ratios determined for the positive and negative controls must lie within the limits stated for the relevant test kit lot. A quality control certificate containing these reference values is included. If the values specified for the controls are not achieved, the test results may be inaccurate and the test should be repeated.
The binding activity of the antibodies and the activity of the enzyme used is temperature-dependent. It is therefore recommended using a thermostat in all three incubation steps. The higher the room temperature (+18°C to +25°C) during incubation steps, the greater will be the extinction. Corresponding variations apply also to the incubation times. However, the calibrators are subject to the same influences, with the result that such variations will be largelycompensated in the calculation of the result.
The microplate wells were coated with the recombinant Epstein-Barr virus early antigen diffuse. The protein was expressed in E. coli and the molecular weight is 45 kDa.
Detection Limit
The lower detection limit is defined as the mean value of an analyte-free sample plus three times the standard deviation and is the smallest detectable antibody titer. The lower detection limit of the EBV- EA-D IgG ELISA kit is 0.8 RU/ml.
General Description
Since early EBV antigens (early antigen, EA) are expressed in the lytic replication phase, the detection of specific antibodies using the Anti-EBV-EA-D IgG ELISA Kit can contribute to supporting the diagnosis of active EBV infections. Results should always be interpreted within the context of clinical symptoms and with respect to further laboratory diagnostic analyses.


Have you cited DEIA329 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Extranodal NK/T Cell Lymphoma, Nasal Type with Palatal Involvement: A Rare Case Report and Literature Review


Authors: Andreou, Anastasia; Thermos, Grigorios; Sklavounou-Andrikopoulou, Alexandra

T-cell lymphomas are infrequently encountered in the head and neck area, with the most common subtype being Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT). ENKTL-NT shows a predilection for midline facial structures presenting with ulcerative destructive lesions, whereas palatal involvement is one of the most prominent signs from the oral cavity. Herein, we describe a case of a 76-year-old Greek man with nasal obstruction and an extensive painful necrotic ulcer with ragged borders on the left distal portion of the soft palate and palatine tonsil of 4-months duration. After an initial non-diagnostic biopsy from the nasopharynx, a second incisional biopsy from the palatal lesions was performed. Histopathology was suggestive of an angiocentric lymphoproliferative neoplasm and immunohistochemical examination and in situ hybridization for EBV RNA led to a final diagnosis of ENKTL-NT. The patient was placed under combined chemotherapy and radiotherapy and no recurrence has been noted. Additionally, a retrospective review of the cases in the English literature with an established diagnosis of ENTKL-NT between 2000 and 2019, based on the latest WHO classification of Head and Neck tumors, is performed.

Smoking and Epstein-Barr virus infection in multiple sclerosis development


Authors: Hedstrom, Anna Karin; Huang, Jesse; Brenner, Nicole; Butt, Julia; Hillert, Jan; Waterboer, Tim; Kockum, Ingrid; Olsson, Tomas; Alfredsson, Lars

It is unclear whether smoking interacts with different aspects of Epstein-Barr virus (EBV) infection with regard to multiple sclerosis (MS) risk. We aimed to investigate whether smoking acts synergistically with elevated EBNA-1 antibody levels or infectious mononucleosis (IM) history regarding MS risk. Two Swedish population-based case-control studies were used (6,340 cases and 6,219 matched controls). Subjects with different smoking, EBNA-1 and IM status were compared regarding MS risk, by calculating odds ratios (OR) with 95% confidence intervals (CI) employing logistic regression. Potential interaction on the additive scale was evaluated by calculating the attributable proportion due to interaction (AP). Current and past smokers had higher EBNA-1 antibody levels than never smokers (p < 0.0001). There was an additive interaction between current smoking and high EBNA-1 antibody levels (AP 0.3, 95% CI 0.2-0.4), but not between past smoking and high EBNA-1 antibody levels (AP 0.01, 95% CI -0.1 to 0.1), with regard to MS risk. An interaction also occurred between current smoking and IM history (AP 0.2, 95% CI 0.004-0.4), but not between past smoking and IM history (AP -0.06, 95% CI -0.4 to 0.3). Current smoking increases EBNA-1 antibody levels and acts synergistically with both aspects of EBV infection to increase MS risk, indicating that there is at least one pathway to disease in which both risk factors are involved.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket